Eribulin
Phase 2Withdrawn 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Trial Timeline
Feb 26, 2019 → Apr 14, 2020
NCT ID
NCT03637868About Eribulin
Eribulin is a phase 2 stage product being developed by Eisai for Metastatic Breast Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03637868. Target conditions include Metastatic Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03840772 | Phase 2 | Completed |
| NCT03637868 | Phase 2 | Withdrawn |
| NCT03331250 | Phase 2 | Active |
| NCT03027245 | Pre-clinical | Completed |
| NCT01669252 | Phase 2 | Completed |
| NCT00908908 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Breast Cancer